NCT07508319Recruiting
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 19 Nov 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- European Institute of Oncology
- Diseases
- Head and neck cancer
- NCT number
- NCT07508319
What you commit to
- Study type: Observational
- Planned participants: 3
- From 19 Nov 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
- Immunosuppressive therapy.
Other illness
- Congenital or acquired immunodeficiency disorders.
- Synchronous malignancies.
Age
- Age \<18 years or absence of research consent.
Who the study is looking for
- Histopathological diagnosis of laryngeal dysplasia.
- Age \>18 years and informed consent.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| European Institute of Oncology Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.